awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41
Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
P2860
Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
37c29a6f29d2ef567c5d11202d9f0600c15d00eb
P2860
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.